| Name | Title | Contact Details |
|---|
BDF is a Morristown, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
PhotoMedex is a leader in the dermatology market, committed to the Science of Skin Health in disease management and skin rejuvenation. We focus our efforts where we can make meaningful differences in dermatological applications for psoriasis and vitiligo, therapeutic skin care and LED therapy for acne and photodamage. Our Purpose, to provide branded dermatological solutions of superior value to improve patients` lives now and into the future, is our common goal and leads our thinking. The results of which will be realized in physicians and patients rewarding us with winning sales, profit and equity generation. Our commitment to safety and efficacy is reflected in our dedication to scientific development and has led to a broad range of FDA clearances. XTRAC was the first FDA market-cleared excimer laser system for the treatment of dermatological applications, including psoriasis and vitiligo. The Omnilux LED system carries FDA clearances for skin rejuvenation, acne and pain management. Neova, the science of skin care, holds dozens of patents on its clinically proven Copper Peptide technology for skin health, hair care and wound care.
IARP Headquarters is a Santa Cruz, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Intrigma is a leader in medical scheduling solutions that deliver bottom-line impact to medical groups, hospitals and hospital systems.
Repertoire Immune Medicines is working to unleash the remarkable power of the human immune system to prevent, treat or cure cancer, autoimmune conditions, and infectious diseases. Repertoire scientists created and developed a suite of technologies for its DECODE discovery and DEPLOY product platforms that allow in-depth characterization of the immune synapse and the ability to rationally design, and clinically develop, multi-clonal immune medicines. The company is currently conducting experimental medicine clinical trials using autologous T cells primed against cancer antigens and tethered to IL-15.